|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
1995
|
|
gptkbp:ATCCode
|
N02AX02
|
|
gptkbp:availableOn
|
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:tramadol
|
|
gptkbp:CASNumber
|
27203-92-5
|
|
gptkbp:cause
|
allergic reactions
withdrawal symptoms
|
|
gptkbp:chemicalFormula
|
C16H25NO2
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
severe respiratory depression
acute intoxication with alcohol
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:eliminationHalfLife
|
6.3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ultram
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
gptkb:SSRIs
CYP2D6 inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 12
patients with severe kidney impairment
patients with severe liver impairment
|
|
gptkbp:overdoseSymptoms
|
coma
seizures
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
seizures
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
headache
|
|
gptkbp:usedFor
|
pain relief
|
|
gptkbp:bfsParent
|
gptkb:Tramadol
gptkb:tramadol
|
|
gptkbp:bfsLayer
|
7
|